Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis
To analyze the in vivo effect of Escherichia coli Nissle 1917 (EcN) with different courses and different doses to Sprague–Dawley rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis.
The probiotic was orally administered with different courses of treatment (with or without pre-administration) and different doses (107–109 CFU/day) to Sprague–Dawley rats with TNBS-induced colitis. Therapeutic effects, levels of cytokine in serum, mRNA and protein expression were analyzed.
Oral EcN administration after TNBS-induced improved colitis dose dependently. In parallel, a reduction of disease activity index and colonic MPO activity together with a decreased level of TNF-α and a trend of increased IL-10 expression was detected. Pre-administration of 107 CFU/day EcN to TNBS-treated rats resulted in a significant protection against inflammatory response and colons isolated from these rats exhibited a more pronounced expression of ZO-1 than the other groups. In the group of pre-administration of 109 CFU/day, the condition was not improved but deteriorated.
This study convincingly demonstrates that pre-administration of probiotic EcN with low dose is able to protect colitis of rats and mediate up-regulation of ZO-1 expression, but long-term of high-dose EcN may do harm to colitis.
KeywordsProbiotic Trinitrobenzene sulfonic acid Myeloperoxidase Tumor necrosis factor-alpha Interleukin-10
This study was supported by grants from the National Scientific Support Project (nos. 20100202, 02012BAI06B03 and BSW11J013), National Natural Science Foundation of China (Nos. 81322037 and 81370504) and National Excellent Doctoral Dissertation of PR China (No. 201182).
Conflict of interest
There are no conflicts of interest to disclose in this paper.
- 7.Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle, a novel effect of a probiotic bacterium. Infect Immun. 1917;2004(72):5750–8.Google Scholar
- 17.Schultz M. Clinical use of E. coli Nissle, in inflammatory bowel disease. Inflamm Bowel Dis. 1917;2008(14):1012–8.Google Scholar
- 19.Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of digestive and metabolic diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42:979–83.CrossRefPubMedGoogle Scholar
- 25.Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Bailon E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol. 2009;157:1024–33.CrossRefPubMedCentralPubMedGoogle Scholar
- 26.Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol. 2004;40:223–9.CrossRefPubMedGoogle Scholar